Education
About Us
Working with TipRanks
Follow Us
Halozyme Therapeutics (HALO)
NASDAQ:HALO
Total Valuation
Halozyme has a market cap or net worth of $8.64B. The enterprise value is $8.21B.
Market Cap$8.64B
Enterprise Value$8.21B
Share Statistics
Halozyme has 118,017,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding118,017,000
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Halozyme’s return on equity (ROE) is 6.49 and return on invested capital (ROIC) is 23.59%.
Return on Equity (ROE)6.49
Return on Assets (ROA)0.13
Return on Invested Capital (ROIC)23.59%
Return on Capital Employed (ROCE)0.35
Revenue Per Employee3.99M
Profits Per Employee905.40K
Employee Count350
Asset Turnover0.55
Inventory Turnover1.73
Valuation Ratios
The current PE Ratio of Halozyme is 28.9. Halozyme’s PEG ratio is -1.04.
PE Ratio28.9
PS Ratio5.77
PB Ratio165.22
Price to Fair Value165.22
Price to FCF12.51
Price to Operating Cash Flow12.82
PEG Ratio-1.04
Income Statement
In the last 12 months, Halozyme had revenue of 1.40B and earned 316.89M in profits. Earnings per share was 2.64.
Revenue1.40B
Gross Profit1.09B
Operating Income816.29M
Pretax Income466.88M
Net Income316.89M
EBITDA904.34M
Earnings Per Share (EPS)2.64
Cash Flow
In the last 12 months, operating cash flow was 651.56M and capital expenditures -6.97M, giving a free cash flow of 644.59M billion.
Operating Cash Flow651.56M
Free Cash Flow644.59M
Free Cash Flow per Share5.46
Dividends & Yields
Halozyme pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.42
52-Week Price Change21.33%
50-Day Moving Average71.39
200-Day Moving Average65.80
Relative Strength Index (RSI)41.79
Average Volume (3m)1.88M
Important Dates
Halozyme upcoming earnings date is May 12, 2026, After Close (Confirmed).
Last Earnings DateFeb 17, 2026
Next Earnings DateMay 12, 2026
Ex-Dividend Date―
Financial Position
Halozyme as a current ratio of 4.66, with Debt / Equity ratio of 0.00%
Current Ratio4.66
Quick Ratio3.66
Debt to Market Cap0.00
Net Debt to EBITDA-0.15
Interest Coverage Ratio45.03
Taxes
In the past 12 months, Halozyme has paid 149.99M in taxes.
Income Tax149.99M
Effective Tax Rate0.32
Enterprise Valuation
Halozyme EV to EBITDA ratio is 8.77, with an EV/FCF ratio of 12.30.
EV to Sales5.68
EV to EBITDA8.77
EV to Free Cash Flow12.30
EV to Operating Cash Flow12.17
Balance Sheet
Halozyme has $142.82M in cash and marketable securities with $0.00 in debt, giving a net cash position of $142.82M billion.
Cash & Marketable Securities$142.82M
Total Debt$0.00
Net Cash$142.82M
Net Cash Per Share$1.21
Tangible Book Value Per Share-$12.63
Margins
Gross margin is 81.95%, with operating margin of 58.45%, and net profit margin of 22.69%.
Gross Margin81.95%
Operating Margin58.45%
Pretax Margin33.43%
Net Profit Margin22.69%
EBITDA Margin64.75%
EBIT Margin58.45%
Analyst Forecast
The average price target for Halozyme is $83.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$83.50
Price Target Upside17.64% Upside
Analyst ConsensusModerate Buy
Analyst Count7
Revenue Growth Forecast31.19%
EPS Growth Forecast59.01%